The Experts below are selected from a list of 93 Experts worldwide ranked by ideXlab platform
Harvey G. Klein - One of the best experts on this subject based on the ideXlab platform.
-
From Leukocyte reduction to Leukocyte Transfusion: the immunological effects of transfused Leukocytes.
Best Practice & Research Clinical Haematology, 2000Co-Authors: Jong‐hoon Lee, Harvey G. KleinAbstract:In Transfusion medicine, mononuclear Leukocytes have been studied more often as contaminants of red blood cells or platelets responsible for adverse Transfusion outcomes than as therapeutic cells; Leukocyte Transfusion has been effective in augmenting recipient immunity only in limited clinical situations. Studies in Leukocyte reduction and Leukocyte Transfusion have progressed separately as if the Leukocytes' adverse and therapeutic effects result from different immunological mechanisms. With growing clinical experience, however, it is increasingly clear that some adverse immune effects may be exploited for therapeutic benefit. Advances in clinical immunology, understanding of the variety of cells and functions in the Leukocyte fraction of blood, and blood component preparation technology may lead to new ways of deriving immunological benefit from transfused blood Leukocytes while minimizing their adverse effects. This chapter reviews the current uses of Leukocyte reduction and mononuclear Leukocyte Transfusion, with an emphasis on the relationship between Transfusion-associated graft-versus-host disease and donor lymphocyte infusion in controlling relapsed leukaemias.
Max D. Cooper - One of the best experts on this subject based on the ideXlab platform.
-
Leukocyte Transfusion-associated granulocyte responses in a patient with X-linked hyper-IgM syndrome.
Journal of clinical immunology, 1998Co-Authors: T. Prescott Atkinson, Carol A. Smith, Yen Ming Hsu, Ellen Garber, Thomas H. Howard, Josef T. Prchal, Michael P. Everson, Max D. CooperAbstract:X-linked hyper-IgM syndrome (XHIM) is a severe congenital immunodeficiency caused by mutations in CD154 (CD40 ligand, gp39), the T cell ligand for CD40 on B cells. Chronic or cyclic neutropenia is a frequent complicating feature that heightens susceptibility to severe infections. We describe a patient with a variant of XHIM who produced elevated levels of serum IgA as well as IgM and suffered from chronic severe neutropenia. Eight of ten Leukocyte Transfusions with cells from a maternal aunt, performed because of mucosal infections, resulted in similar episodes of endogenous granulocyte production. Transfection studies with the mutant CD154 protein indicate that the protein is expressed at the cell surface and forms an aberrant trimer that does not interact with CD40. The data suggest that allogeneic cells from the patient's aunt, probably activated T cells bearing functional CD154, may interact with CD40+ recipient cells to produce maturation of myeloid precursors in the bone marrow.
Hitomi Nagayama - One of the best experts on this subject based on the ideXlab platform.
-
IL-2/LAK therapy for refractory acute monoblastic leukemia relapsing after unrelated allogeneic bone marrow transplantation.
Bone marrow transplantation, 1999Co-Authors: Hitomi Nagayama, Satoru Takahashi, Akihiro Tojo, Kenzaburo Tani, Tsuneo A. Takahashi, Kazuo Ogami, Kenji Ikebuchi, Shigetaka AsanoAbstract:Leukemia relapse is a major cause of treatment failure after allogeneic bone marrow transplantation. We administered recombinant interleukin-2 (rIL-2) to a patient who relapsed after unrelated allogeneic bone marrow transplantation (uBMT). While the number of peripheral blood monoblastic leukemia cells increased after administration of rIL-2, the patient achieved durable remission for 5 months after low-dose chemotherapy followed by adoptive transfer of engrafted graft-derived lymphokine-activated killer (LAK) cells. Following the disappearance of the blast cells, however, both cutaneous and liver GVHD were exacerbated. Administration of rIL-2 and adoptive transfer of graft-derived LAK cells are considered to be possible choices for the treatment of acute leukemia relapsing after uBMT when donor Leukocyte Transfusion is not available.
-
Fatal GVHD demonstrating an involvement of respiratory muscle following donor Leukocyte Transfusion (DLT)
Bone marrow transplantation, 1997Co-Authors: Yasuo Oshima, Satoru Takahashi, Hitomi Nagayama, K. Nishiwaki, Yukio Kobayashi, Akihiro Tojo, Shinichiro Okamoto, Kenzaburo Tani, Keiya Ozawa, T. WakabayashiAbstract:A 41-year-old female patient with AML, who relapsed after an allogeneic BMT from her HLA-identical sister, was treated by a donor Leukocyte Transfusion (DLT). Thereafter, bone marrow aplasia accompanied by the disappearance of leukemic blasts following the GVHD was observed. The patient died of chronic GVHD with respiratory muscle involvement 19 months after the DLT. Although the DLT was considered helpful in suppressing the proliferation of the leukemic cells, it might also have caused the severe GVHD observed in this case. Efforts to separate the lymphocyte clones responsible for GVL from those for the GVHD thus appear to be necessary for the further development of the therapeutic approach, so-called DLT.
Satoru Takahashi - One of the best experts on this subject based on the ideXlab platform.
-
IL-2/LAK therapy for refractory acute monoblastic leukemia relapsing after unrelated allogeneic bone marrow transplantation.
Bone marrow transplantation, 1999Co-Authors: Hitomi Nagayama, Satoru Takahashi, Akihiro Tojo, Kenzaburo Tani, Tsuneo A. Takahashi, Kazuo Ogami, Kenji Ikebuchi, Shigetaka AsanoAbstract:Leukemia relapse is a major cause of treatment failure after allogeneic bone marrow transplantation. We administered recombinant interleukin-2 (rIL-2) to a patient who relapsed after unrelated allogeneic bone marrow transplantation (uBMT). While the number of peripheral blood monoblastic leukemia cells increased after administration of rIL-2, the patient achieved durable remission for 5 months after low-dose chemotherapy followed by adoptive transfer of engrafted graft-derived lymphokine-activated killer (LAK) cells. Following the disappearance of the blast cells, however, both cutaneous and liver GVHD were exacerbated. Administration of rIL-2 and adoptive transfer of graft-derived LAK cells are considered to be possible choices for the treatment of acute leukemia relapsing after uBMT when donor Leukocyte Transfusion is not available.
-
Fatal GVHD demonstrating an involvement of respiratory muscle following donor Leukocyte Transfusion (DLT)
Bone marrow transplantation, 1997Co-Authors: Yasuo Oshima, Satoru Takahashi, Hitomi Nagayama, K. Nishiwaki, Yukio Kobayashi, Akihiro Tojo, Shinichiro Okamoto, Kenzaburo Tani, Keiya Ozawa, T. WakabayashiAbstract:A 41-year-old female patient with AML, who relapsed after an allogeneic BMT from her HLA-identical sister, was treated by a donor Leukocyte Transfusion (DLT). Thereafter, bone marrow aplasia accompanied by the disappearance of leukemic blasts following the GVHD was observed. The patient died of chronic GVHD with respiratory muscle involvement 19 months after the DLT. Although the DLT was considered helpful in suppressing the proliferation of the leukemic cells, it might also have caused the severe GVHD observed in this case. Efforts to separate the lymphocyte clones responsible for GVL from those for the GVHD thus appear to be necessary for the further development of the therapeutic approach, so-called DLT.
Akihiro Tojo - One of the best experts on this subject based on the ideXlab platform.
-
IL-2/LAK therapy for refractory acute monoblastic leukemia relapsing after unrelated allogeneic bone marrow transplantation.
Bone marrow transplantation, 1999Co-Authors: Hitomi Nagayama, Satoru Takahashi, Akihiro Tojo, Kenzaburo Tani, Tsuneo A. Takahashi, Kazuo Ogami, Kenji Ikebuchi, Shigetaka AsanoAbstract:Leukemia relapse is a major cause of treatment failure after allogeneic bone marrow transplantation. We administered recombinant interleukin-2 (rIL-2) to a patient who relapsed after unrelated allogeneic bone marrow transplantation (uBMT). While the number of peripheral blood monoblastic leukemia cells increased after administration of rIL-2, the patient achieved durable remission for 5 months after low-dose chemotherapy followed by adoptive transfer of engrafted graft-derived lymphokine-activated killer (LAK) cells. Following the disappearance of the blast cells, however, both cutaneous and liver GVHD were exacerbated. Administration of rIL-2 and adoptive transfer of graft-derived LAK cells are considered to be possible choices for the treatment of acute leukemia relapsing after uBMT when donor Leukocyte Transfusion is not available.
-
Fatal GVHD demonstrating an involvement of respiratory muscle following donor Leukocyte Transfusion (DLT)
Bone marrow transplantation, 1997Co-Authors: Yasuo Oshima, Satoru Takahashi, Hitomi Nagayama, K. Nishiwaki, Yukio Kobayashi, Akihiro Tojo, Shinichiro Okamoto, Kenzaburo Tani, Keiya Ozawa, T. WakabayashiAbstract:A 41-year-old female patient with AML, who relapsed after an allogeneic BMT from her HLA-identical sister, was treated by a donor Leukocyte Transfusion (DLT). Thereafter, bone marrow aplasia accompanied by the disappearance of leukemic blasts following the GVHD was observed. The patient died of chronic GVHD with respiratory muscle involvement 19 months after the DLT. Although the DLT was considered helpful in suppressing the proliferation of the leukemic cells, it might also have caused the severe GVHD observed in this case. Efforts to separate the lymphocyte clones responsible for GVL from those for the GVHD thus appear to be necessary for the further development of the therapeutic approach, so-called DLT.